114 related articles for article (PubMed ID: 38029831)
1. Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Mostaghim A; Minkove S; Aguilar-Company J; Ruiz-Camps I; Eremiev-Eremiev S; Dettorre GM; Fox L; Tondini C; Brunet J; Carmona-García M; Lambertini M; Bower M; Newsom-Davis T; Sharkey R; Pria AD; Rossi M; Plaja A; Salazar R; Sureda A; Prat A; Michalarea V; Van Hemelrijck M; Sita-Lumsden A; Bertuzzi A; Rimassa L; Rossi S; Rizzo G; Pedrazzoli P; Lee AJ; Murphy C; Belessiotis K; Diamantis N; Mukherjee U; Pommeret F; Stoclin A; Martinez-Vila C; Bruna R; Gaidano G; D'Avanzo F; Gennari A; Athale J; Eichacker P; Pinato DJ; Torabi-Parizi P; Cortellini A;
Int J Infect Dis; 2024 Feb; 139():13-20. PubMed ID: 38029831
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries.
Cortellini A; Dettorre GM; Dafni U; Aguilar-Company J; Castelo-Branco L; Lambertini M; Gennatas S; Angelis V; Sita-Lumsden A; Rogado J; Pedrazzoli P; Viñal D; Prat A; Rossi M; Berardi R; Alonso-Gordoa T; Grisanti S; Dimopoulou G; Queirolo P; Pradervand S; Bertuzzi A; Bower M; Arnold D; Salazar R; Tucci M; Harrington KJ; Mazzoni F; Mukherjee U; Tsourti Z; Michielin O; Pommeret F; Brunet J; Vincenzi B; Tonini G; Patriarca A; Biello F; Krengli M; Tabernero J; Pentheroudakis G; Gennari A; Peters S; Romano E; Pinato DJ
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36450384
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.
Pinato DJ; Tabernero J; Bower M; Scotti L; Patel M; Colomba E; Dolly S; Loizidou A; Chester J; Mukherjee U; Zambelli A; Dalla Pria A; Aguilar-Company J; Ottaviani D; Chowdhury A; Merry E; Salazar R; Bertuzzi A; Brunet J; Lambertini M; Tagliamento M; Pous A; Sita-Lumsden A; Srikandarajah K; Colomba J; Pommeret F; Seguí E; Generali D; Grisanti S; Pedrazzoli P; Rizzo G; Libertini M; Moss C; Evans JS; Russell B; Harbeck N; Vincenzi B; Biello F; Bertulli R; Liñan R; Rossi S; Carmona-García MC; Tondini C; Fox L; Baggi A; Fotia V; Parisi A; Porzio G; Saponara M; Cruz CA; García-Illescas D; Felip E; Roqué Lloveras A; Sharkey R; Roldán E; Reyes R; Earnshaw I; Ferrante D; Marco-Hernández J; Ruiz-Camps I; Gaidano G; Patriarca A; Bruna R; Sureda A; Martinez-Vila C; Sanchez de Torre A; Cantini L; Filetti M; Rimassa L; Chiudinelli L; Franchi M; Krengli M; Santoro A; Prat A; Van Hemelrijck M; Diamantis N; Newsom-Davis T; Gennari A; Cortellini A;
Lancet Oncol; 2021 Dec; 22(12):1669-1680. PubMed ID: 34741822
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study.
Pinato DJ; Aguilar-Company J; Ferrante D; Hanbury G; Bower M; Salazar R; Mirallas O; Sureda A; Plaja A; Cucurull M; Mesia R; Townsend S; Jackson A; Dalla Pria A; Newsom-Davis T; Handford J; Sita-Lumsden A; Apthorp E; Vincenzi B; Bertuzzi A; Brunet J; Lambertini M; Maluquer C; Pedrazzoli P; Biello F; Sinclair A; Bawany S; Khalique S; Rossi S; Rogers L; Murphy C; Belessiotis K; Carmona-García MC; Sharkey R; García-Illescas D; Rizzo G; Perachino M; Saoudi-Gonzalez N; Doonga K; Fox L; Roldán E; Gaidano G; Ruiz-Camps I; Bruna R; Patriarca A; Martinez-Vila C; Cantini L; Zambelli A; Giusti R; Mazzoni F; Caliman E; Santoro A; Grosso F; Parisi A; Queirolo P; Aujayeb A; Rimassa L; Prat A; Tucci M; Libertini M; Grisanti S; Mukherjee U; Diamantis N; Fusco V; Generali D; Provenzano S; Gennari A; Tabernero J; Cortellini A;
Lancet Oncol; 2022 Jul; 23(7):865-875. PubMed ID: 35660139
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Impact of Immune Checkpoint Inhibitors on COVID-19 Severity in Patients with Cancer.
Tan R; Yun C; Seetasith A; Sheinson D; Walls R; Ngwa I; Reddy JC; Zhang Q; Secrest MH; Lambert P; Sarsour K
Oncologist; 2022 Mar; 27(3):236-243. PubMed ID: 35274714
[TBL] [Abstract][Full Text] [Related]
7. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
9. Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors.
Gilbert D; Hu J; Medina T; Kessler ER; Lam ET
Hum Vaccin Immunother; 2023 Dec; 19(1):2207438. PubMed ID: 37157982
[TBL] [Abstract][Full Text] [Related]
10. Rethinking the management of immune checkpoint inhibitor-related adrenal insufficiency in cancer patients during the COVID-19 pandemic.
Yuen KCJ; Mortensen MJ; Azadi A; Fonkem E; Findling JW
Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00246. PubMed ID: 34268454
[TBL] [Abstract][Full Text] [Related]
11. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition.
Rogiers A; Pires da Silva I; Tentori C; Tondini CA; Grimes JM; Trager MH; Nahm S; Zubiri L; Manos M; Bowling P; Elkrief A; Papneja N; Vitale MG; Rose AAN; Borgers JSW; Roy S; Mangana J; Pimentel Muniz T; Cooksley T; Lupu J; Vaisman A; Saibil SD; Butler MO; Menzies AM; Carlino MS; Erdmann M; Berking C; Zimmer L; Schadendorf D; Pala L; Queirolo P; Posch C; Hauschild A; Dummer R; Haanen J; Blank CU; Robert C; Sullivan RJ; Ascierto PA; Miller WH; Stephen Hodi F; Suijkerbuijk KPM; Reynolds KL; Rahma OE; Lorigan PC; Carvajal RD; Lo S; Mandala M; Long GV
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468556
[TBL] [Abstract][Full Text] [Related]
13. Prediction of severe immune-related adverse events requiring hospital admission in patients on immune checkpoint inhibitors: study of a population level insurance claims database from the USA.
Kalinich M; Murphy W; Wongvibulsin S; Pahalyants V; Yu KH; Lu C; Wang F; Zubiri L; Naranbhai V; Gusev A; Kwatra SG; Reynolds KL; Semenov YR
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789879
[TBL] [Abstract][Full Text] [Related]
14. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
15. Impact of COVID-19 on patients with rheumatic complications of cancer immunotherapy: results of a registry survey.
Ghosh N; Tirpack A; Chan KK; Bass AR
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33067320
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non-Small Cell Lung Cancer.
Kawachi H; Yamada T; Tamiya M; Negi Y; Goto Y; Nakao A; Shiotsu S; Tanimura K; Takeda T; Okada A; Harada T; Date K; Chihara Y; Hasegawa I; Tamiya N; Ishida M; Katayama Y; Morimoto K; Iwasaku M; Tokuda S; Kijima T; Takayama K
JAMA Netw Open; 2023 Jul; 6(7):e2322915. PubMed ID: 37432682
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Ruiz JI; Lopez-Olivo MA; Geng Y; Suarez-Almazor ME
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36746512
[TBL] [Abstract][Full Text] [Related]
18. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.
; Pinato DJ; Patel M; Scotti L; Colomba E; Dolly S; Loizidou A; Chester J; Mukherjee U; Zambelli A; Dalla Pria A; Aguilar-Company J; Bower M; Salazar R; Bertuzzi A; Brunet J; Lambertini M; Tagliamento M; Pous A; Sita-Lumsden A; Srikandarajah K; Colomba J; Pommeret F; Seguí E; Generali D; Grisanti S; Pedrazzoli P; Rizzo G; Libertini M; Moss C; Evans JS; Russell B; Harbeck N; Vincenzi B; Biello F; Bertulli R; Ottaviani D; Liñan R; Rossi S; Carmona-García MC; Tondini C; Fox L; Baggi A; Fotia V; Parisi A; Porzio G; Queirolo P; Cruz CA; Saoudi-Gonzalez N; Felip E; Roqué Lloveras A; Newsom-Davis T; Sharkey R; Roldán E; Reyes R; Zoratto F; Earnshaw I; Ferrante D; Marco-Hernández J; Ruiz-Camps I; Gaidano G; Patriarca A; Bruna R; Sureda A; Martinez-Vila C; Sanchez de Torre A; Berardi R; Giusti R; Mazzoni F; Guida A; Rimassa L; Chiudinelli L; Franchi M; Krengli M; Santoro A; Prat A; Tabernero J; Van Hemelrijck M; Diamantis N; Gennari A; Cortellini A
JAMA Oncol; 2022 Jan; 8(1):114-122. PubMed ID: 34817562
[TBL] [Abstract][Full Text] [Related]
19. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibition therapy for advanced skin cancer in patients with concomitant hematological malignancy: a retrospective multicenter DeCOG study of 84 patients.
Leiter U; Loquai C; Reinhardt L; Rafei-Shamsabadi D; Gutzmer R; Kaehler K; Heinzerling L; Hassel JC; Glutsch V; Sirokay J; Schlecht N; Rübben A; Gambichler T; Schatton K; Pfoehler C; Franklin C; Terheyden P; Haferkamp S; Mohr P; Bischof L; Livingstone E; Zimmer L; Weichenthal M; Schadendorf D; Meiwes A; Keim U; Garbe C; Becker JC; Ugurel S
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]